One-pot conversion of thebaine to hydrocodone and synthesis of neopinone ketal

Journal of Organic Chemistry

Volumn 74, Issue 2, 2009, Pages 747-752

  Carroll, Robert J ^a   Leisch, Hannes ^a   Rochon, Lena ^a   Hudlicky, Tomas ^a   Cox, D Phillip ^b  

^a BROCK UNIVERSITY   (Canada)

^b Noramco Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID-CATALYZED HYDROLYSIS; AQUEOUS MEDIUMS; DI ENOLS; DIIMIDE; HYDROGENATION CATALYSTS; ONE POTS; ONE-POT PROCEDURES; P-TOLUENE SULFONIC ACIDS; PALLADIUM CATALYSIS; SPECTRAL DATUM; TWO-STEP PROTOCOLS;

ACIDS; CATALYSIS; ETHERS; ETHYLENE; HYDROGENATION; PALLADIUM;

ETHYLENE GLYCOL;

ACETAL DERIVATIVE; ETHYLENE GLYCOL; HYDROCODONE; NEOPINONE KETAL; PALLADIUM; THEBAINE; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; CYCLIC 1,2 ETHANEDIYL ACETAL 8,14 DIDEHYDRO 4,5 EPOXY 3 METHOXY 17 METHYLMORPHINAN 6 ONE; CYCLIC-1,2-ETHANEDIYL ACETAL 8,14-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE; MORPHINAN DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; CATALYSIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; HYDROGENATION; ONE POT SYNTHESIS; REDUCTION KINETICS; SYNTHESIS; CHEMISTRY;

HYDROCODONE; MORPHINANS; THEBAINE;

EID: 60849111979     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo802454v     Document Type: Article

References (33)

1. (a) Zezula, J.; Hudlicky, T. Synlett 2005, 388.
2. (b) Novak, B. H.; Hudlicky, T.; Reed, J. W.; Mulzer, J.; Trauner, D. Curr. Org. Chem. 2000, 4, 343.
3. (c) Butora, G.; Hudlicky, T. Organic Synthesis: Theory and Applications; Hudlicky, T., Ed.; JAI Press: Stamford, CT, 1998; Vol. 4, pp 1-51.
4. (d) Hudlicky, T.; Butora, G.; Fearnley, S.; Gum, A.; Stabile, M. In Studies in Natural Products Chemistry; Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, 1996; Vol. 18, p 43.
5. Report of the International Narcotics Control Board for 2005, ISBN 92-1-148209-7 ISSN 0257-3717, Page 17.
6. For production quotas of morphine alkaloids for the U.S., see: http://www.deadiversion.usdoj.gov/quotas/quota-history.htm.
7. The Electronic Orange Book, http://www.fda.gov/cder/ob/default.htm, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,Office of Pharmaceutical Science, Office of Generic Drugs.
8. (a) Millgate, A. G.; Pogson, B. J.; Wilson, I. W.; Kutchan, T. M.; Zenk, M. H.; Gerlach, W. L.; Fist, A. J.; Larkin, P. J. Nature 2004, 431, 413.
9. (b) Fist, A. J.; Byrne, C. J.; Gerlach, W. L. US 6067749; US 6376221; US 6723894.
10. Freund, M.; Speyer, E. J. Prakt. Chem. 1916, 94, 135.
11. Seki, I. Takamine Kenkuusho Nempo 1960, 12, 52. [CA:55:38149].
12. (a) Krassnig, R.; Hederer, C.; Schmidhammer, H. Arch. Pharm. 1996, 329, 325.
13. (b) Francis, C. A.; Lin, Z.; Kaldahl, C. A.; Antczak, K. G.; Kumar, V. US 2005/0038251 A1.
14. (c) Casner, M. L.; Dung, J. S.; Keskeny, E. M.; Luo, J.; Lopez, D.; Quiiioa, E.; Riguera, R. J. Org. Chem. 2000, 65, 4671 US 2006111383; alternative methods for C-14 hydroxylation include a photochemical approach.
15. (a) ICH safety guidelines (ICH S2A, 1995;ICH S2B, 1997).
16. (b) Mueller, L.; Mauthe, R. J.; Riley, C. M.; Andino, M. M.; De Antonis, D.; Beels, C.; DeGeorge, J.; De Knaep, A. G. M.; Ellison, D.; Fagerland, J. A.; Frank, R.; Fritschel, B.; Galloway, S.; Harpur, E.; Humfrey, C. D. N.; Jacks, A. S.; Jagota, N.; Mackinnon, J.; Mohan, G.; Ness, D. K.; O'Donovan, M. R.; Smith, M. D.; Vudathala, G.; Yotti, L. Regul. Toxicol. Pharmacol. 2006, 44, 198.
17. Barber, R.; Rapoport, H. J. Med. Chem. 1976, 19, 1175.
18. Dauben, W. G.; Baskin, C. P.; Van Riel, H. C. H. A. J. Org. Chem. 1979, 44, 1567.
19. Heathcock, C. H.; Ratcliffe, R. J. Am. Chem. Soc. 1971, 93, 1746.
20. Trauner, D.; Bats, J. W.; Werner, A.; Mulzer, J. J. Org. Chem. 1998, 63, 5908.
21. For examples, see: (a) Conroy, H. J. Am. Chem. Soc. 1955, 77, 5960.
22. (b) Batterham, T. J.; Bell, K. H.; Weiss, U. Aust. J. Chem. 1966, 19, 321, and references cited therein.
23. Moos, W. H.; Gless, R. D.; Rapoport, H. J. J. Org. Chem. 1983, 48, 227.
24. (a) Knoll & Co DE 441613.
25. (b) Knoll & Co GB 225,824.
26. Goto, K.; Shishido, H. Bull. Chem. Soc. Jpn. 1935, 10, 597.
27. (a) Cahn, R. S. J. Chem. Soc. 1933, 1038.
28. (b) Bentley, K. W.; Dyke, S. F.; Marshall, A. R. Tetrahedron 1965, 21, 2553.
29. (a) Schopf, C. Ann. 1927, 452, 232.
30. (b) Janssen, R. H. A. M.; Wijkens, P.; Kruk, C.; Biessels, H. W. A.; Menichini, F.; Theuns, H. G. Phytochemistry 1990, 29, 3331.
31. Leisch, H.; Carroll, R. J.; Hudlicky, T.; Cox, D. P. Tetrahedron Lett. 2007, 48, 3979.
32. Grew, E. L.; Robertson, A. A. US 3812132.
33. The use of thebaine and other morphinans was carried out in accordance with Health Canada guidelines and procedures [licence # 2006/7531].